Challenges Predicting Ligand-Receptor Interactions of Promiscuous Proteins: The Nuclear Receptor PXR by Ekins, Sean et al.
Challenges Predicting Ligand-Receptor Interactions of
Promiscuous Proteins: The Nuclear Receptor PXR
Sean Ekins
1,2,3*, Sandhya Kortagere
4, Manisha Iyer
5, Erica J. Reschly
5, Markus A. Lill
6, Matthew R.
Redinbo
7,8,9, Matthew D. Krasowski
5¤
1Collaborations in Chemistry, Jenkintown, Pennsylvania, United States of America, 2Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland,
United States of America, 3Department of Pharmacology, University of Medicine & Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School, Piscataway,
New Jersey, United States of America, 4Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of
America, 5Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 6Department of Medicinal Chemistry and Molecular
Pharmacology, Purdue University, West Lafaytte, Indiana, United States of America, 7Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina, United States of America, 8Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United
States of America, 9The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
Abstract
Transcriptional regulation of some genes involved in xenobiotic detoxification and apoptosis is performed via the human
pregnane X receptor (PXR) which in turn is activated by structurally diverse agonists including steroid hormones. Activation
of PXR has the potential to initiate adverse effects, altering drug pharmacokinetics or perturbing physiological processes.
Reliable computational prediction of PXR agonists would be valuable for pharmaceutical and toxicological research. There
has been limited success with structure-based modeling approaches to predict human PXR activators. Slightly better
success has been achieved with ligand-based modeling methods including quantitative structure-activity relationship
(QSAR) analysis, pharmacophore modeling and machine learning. In this study, we present a comprehensive analysis
focused on prediction of 115 steroids for ligand binding activity towards human PXR. Six crystal structures were used as
templates for docking and ligand-based modeling approaches (two-, three-, four- and five-dimensional analyses). The best
success at external prediction was achieved with 5D-QSAR. Bayesian models with FCFP_6 descriptors were validated after
leaving a large percentage of the dataset out and using an external test set. Docking of ligands to the PXR structure co-
crystallized with hyperforin had the best statistics for this method. Sulfated steroids (which are activators) were consistently
predicted as non-activators while, poorly predicted steroids were docked in a reverse mode compared to 5a-androstan-3b-
ol. Modeling of human PXR represents a complex challenge by virtue of the large, flexible ligand-binding cavity. This study
emphasizes this aspect, illustrating modest success using the largest quantitative data set to date and multiple modeling
approaches.
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Introduction
Promiscuous proteins generally bind a large array of diverse
ligand structures. These proteins include enzymes like cytochrome
P450s (e.g. CYP3A4, EC 14.13.97), transporters such as P-
glycoprotein (ABCB1), the human ether-a-go-go related gene
(hERG, Kv11.1) potassium channel and nuclear hormone receptors
(NHRs) such as the pregnane X receptor (PXR; NR1I2; also known
as SXR or PAR) [1]. This promiscuous binding may be facilitated
by a very largebindingsite,multiple (overlapping) bindingsites, or a
flexible binding site that can adjust to the size of the ligand. Intrinsic
disorder in the protein may also have a role [2,3]. These proteins
described above are also particularly important as xenobiotic
sensors and represent key mechanisms to respond to toxic stress.
The human PXR [4–6] transcriptionally regulates genes
involved in xenobiotic metabolism and excretion, as well as other
cellular processes such as apoptosis [7–11]. Human PXR has a
very broad specificity for ligands as exemplified by the structurally
diverse array of activators including endogenous (bile acids, steroid
hormones, fat-soluble vitamins) and exogenous (prescription and
herbal drugs, and environmental chemicals) compounds. Activa-
tion of human PXR can cause drug-drug interactions [4,5] or
result in physiological effects ranging from ameliorating cholestatic
injury to the liver, altering bone homeostasis, and causing cell
proliferation [12]. As PXR represents a potential target for
pharmacologic modulation in disease, it is therefore becoming
even more important to develop methods that can identify
whether a molecule is likely to be a PXR agonist [13]. Currently
there are five high-resolution crystal structures of human PXR
[14–18] available in the Protein Data Bank (PDB) (and another
structure to be deposited [19]). The structures have provided
atomic level details that have led to a greater understanding of the
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in ligand-receptor interactions [9,10,12–15]. The co-crystallized
ligands include the natural products hyperforin (active component
of the herbal anti-depressant St. John’s wort) and colupulone (from
hops), the steroid 17b-estradiol, the synthetic compounds
SR12813, T1317 and the antibiotic rifampicin. These ligands
span a range of molecular sizes (M.Wt range 272.38 – 713.81Da,
mean 487.586147.25Da, Table S1) and are predicted as generally
hydrophobic (calculated ALogP [20] 3.54–10.11, mean
5.5462.41). The cavernous ligand binding pocket (LBP) with a
volume .1350 A ˚ 3 accepts molecules of these widely varying
dimensions and chemical properties, and is likely capable of
binding small molecules in multiple orientations [21]. This
complicates overall prediction of whether a small molecule is
likely to be classified as a PXR agonist using traditional structure-
based virtual screening methods like docking [13,22]. With regard
to this, we have previously shown that the widely used structure-
based docking methods FlexX and GOLD performed relatively
poorly in predicting human PXR agonists [7,16] and this is
perhaps not surprising based on the observations described above.
An alternative method, which has been found to be valuable
elsewhere in drug discovery, particularly when there may not be
an available crystal structure of the target protein, uses a ligand-
based approach. In this case a series of small molecule structures
with PXR agonist activity data can be used to facilitate a structure
activity relationship (SAR). When the biological activity data is
continuous this will enable a quantitative structure activity
relationship (QSAR) [23–25]. One widely used computational
technology produces pharmacophores [20–23], which represent
models that encode the key chemical features important for
biological activity. Human PXR agonist pharmacophore models
have been shown to possess hydrophobic, hydrogen bond acceptor
and hydrogen bond donor features, consistent with the crystallo-
graphic structures of human PXR ligand-receptor complexes
[26–29]. These pharmacophore models have predominantly used
structurally diverse ligands in the training set and have the
limitation in most cases of compiling data from multiple
laboratories using different experimental protocols, ultimately
forcing binary classifications of ligands for the training sets (i.e.,
activating versus non-activating). Most of the models so far use
EC50 data, a measure of receptor transactivation. Although
binding assays have been done with human PXR, they are
problematic given the low affinity of most PXR activators. As a
result, there is little radioligand binding data in the literature other
than competition experiments with radiolabeled SR12813.
To date there have been few attempts to build ligand-based
models around a large structurally narrow set of PXR activators.
The absence of large sets of quantitative data for PXR agonists has
restricted QSAR models to a relatively small universe of molecules
compared to the known drugs, drug-like molecules, endobiotics
and xenobiotics in general [30]. The PXR data limitation has
resulted in the use of various machine learning methods (e.g
support vector machine, recursive partitioning etc.) when the
biological data is binary in nature (e.g. activating or binding versus
non-activating / non-binding) [13,22,25,30].
As part of an ongoing analysis of NHRs [25–28], we have
generated a large cadre of experimental data for classes of steroidal
compounds, namely androstanes, estratrienes, pregnanes and bile
acids/salts [31]. The advantages of using steroidal compounds for
QSAR are that they are amenable to common alignments based on
the steroidal backbone. For, example steroids represented the first
datasets used for comparative molecular fields analysis (CoMFA)
[32] and have been widely used as a benchmark for other methods
such as comparative molecular similarity analysis (CoMSIA)[33].
Pharmacophore methods, in contrast, generally do not require the
rigid alignment methods and have found use with more diverse
structure sets [28,31]. Using this large quantitative data set of PXR
activators, we applied various ligand-based computational methods
including Bayesian modeling with 2D fingerprints. We also
compared the results from QSAR approaches to molecular docking
into the six available human PXR crystal structures.
Modeling of a broad specificity receptor such as PXR represents
a challenge for in silico modeling and it is invaluable to know what
approaches prove successful, if any. Ideally, these methods will also
translate to modeling approaches for other broad specificity
enzymes, transporters and ion channels [1], or other promiscuous
proteins [34]. We are not aware of any similar studies using a
comparative approach to predicting ligand-protein interactions for
promiscuous proteins. This study also provides further insights into
PXR-steroid interactions which have not been well studied [19]
and is clinically relevant due to the widespread use of steroidal
compounds and steroid mimics (e.g. oral contraceptives [35], for
inflammation and as cancer treatments etc.) in clinical medicine
[36], as well as the increasing problem of environmental
contamination by endocrine disruptors [24].
Results
Docking
All compounds shown in Table S2 were docked to the six
human PXR crystal structures using GOLD which we have used
previously for docking diverse compounds into the human PXR
structure [22]. All six crystal structures superimposed with a
backbone root mean squared deviation of 0.5 A ˚ suggesting that
they had very similar structures and their co-crystallized ligands
bound to the same binding pocket (Figure S1). The docking scores
for all the compounds (Table S2) were in the range of 36 to 77 for
all the crystal structures and their corresponding Tanimoto
similarity scores to 5a-androstan-3b-ol and the crystal ligand
17b-estradiol using MDL public keys were between 0.4 and 1.
To evaluate docking results, we compared docking scores for
classifying compounds as activators or non-activators of PXR.
Author Summary
Promiscuous proteins generally bind a large array of
diverse ligand structures. This may be facilitated by a very
large binding site, multiple binding sites, or a flexible
binding site that can adjust to the size of the ligand. These
aspects also increase the complexity of predicting whether
a molecule will bind or not to such proteins which
frequently function as exogenous compound sensors to
respond to toxic stress. For example, transporters may
prevent absorption of some molecules, and enzymes may
convert them to more readily excretable compounds (or
alternatively activate them prior to further clearance by
other detoxification enzymes). Nuclear hormone receptors
may respond to ligands and then affect downstream gene
expression to upregulate both enzymes and transporters
to increase the clearance for the same or different
molecules. We have assessed the ability of many different
ligand-based and structure-based computational ap-
proaches to model and predict the activation of human
PXR by steroidal compounds. We find the most effective
computational approach to identify potential steroidal PXR
agonists which are clinically relevant due to their
widespread use in clinical medicine and the presence of
mimics in the environment.
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Table S2 were classified as activators (30 compounds) and non-
activators (89 compounds). These results were compared to the
classification obtained from the docking studies. The overall
accuracy (Q values) were in the range of 35 to 55 % for models
that used 5a-androstan-3b-ol based similarity scores as weights to
the goldscore, while the Q values were in the range of 47 to 58%
for models that were generated with goldscores weighted with 17b-
estradiol based similarity scores (Table 1). The Matthews
coefficient C showed a modest prediction rate with the best score
for docking of compounds to PXR crystal structure 1M13. Further
changing the cutoff values to either 100 mMo r4 0mM did not
improve the prediction rates. The Q value for a model computed
by averaging all the models with 5a-androstan-3b-ol weighted
goldscore was 46% and for the average model with 17b-estradiol
the weighted goldscore was 51%.
Although the overall performance of docking produced rather
modest results for classification the results for individual classes of
compounds was better than average. In the best classification
model (compounds docked to crystal structure 1M13 and weighted
with 17b-estradiol based similarity scores), 20 out of 30 PXR
activators and 49 out of 89 non-activators were predicted
correctly. Among the androstanes, 6 out of 11 compounds were
predicted correctly as activators and 9 out of 14 compounds were
classified as non-activators (Table S2). Among the bile salts, all 4
activators and 22 out of 46 non-activators were predicted
correctly. Among the estratrienes, 5 out of 7 activators were
predicted correctly, while the 4 non-activators were predicted as
activators (Table S2). The reason for this mis-classification was due
to the high similarity scores of the estrogens with 17b-estradiol. In
the pregnane class, 4 out of 7 activators and 16 out of 20 non-
activators were correctly classified (Table S2). Some examples of
molecules in their binding modes with PXR structure 1M13 are
shown in Figure 1.
2D-Classification: Bayesian Models
All 115 compounds shown in Table S2 were used to generate a
Bayesian classification model [37], using a definition of active as a
compound having an EC50 for PXR activation of less than
10 mM. Using molecular function class fingerprints of maximum
diameter 6 (FCFP_6) and 8 interpretable descriptors (AlogP,
molecular weight, rotatable bonds, number of rings, number of
aromatic rings, hydrogen bond acceptor, hydrogen bond donor
and polar surface area) a model was developed with a receiver
operator curve (ROC) statistic for leave one out cross validation
of 0.84. In addition to the leave one out cross validation, further
validation methods were undertaken. After leaving 20% of the
compounds out 100 times the ROC is 0.8460.08, concordance
73.2 %68.94, specificity 69.14%612.12, and sensitivity
84.11%618.04. The Bayesian method appears to have good
model statistics for internal cross validation of steroids. These
statistics suggest the model is stable and not over-trained as the
ROC values are essentially identical to that obtained with leave
one out cross validation.
We have additionally used this model to classify a previously
used diverse molecule test set [13,22]. After removing the steroids
from the test set, the Bayesian PXR model was used to rank 123
molecules (65 activators and 58 non activators). Out of the top 30
molecules scored and ranked with this model 20 (75%) were
classified as activators (EC50 ,100 mM) (Table S3). Even though
the cutoff for activity for the Bayesian model is more stringent it
still appears to be able to predominantly pick out the key
molecular features that contribute to activity in non-steroidal
compounds.
The Bayesian model with FCFP_6 descriptors also enabled the
visualization of substructure fingerprints (Figure 2) that either
contributed positively or negatively to the activity classification. It
appears that all positive contributing substructures are essentially
hydrophobic, while negatively contributing features possess
hydroxyl or other substitutions which are likely not optimally
placed to facilitate interactions with hydrogen bonding features in
PXR. Therefore possession of these hydrogen bond acceptor and
donor features indicated in the steroidal substructures appears to
be related to loss of PXR activation. The method does not readily
identify where these groups should be added in contrast to
methods like docking [13,38].
3D-QSAR and 4D-QSAR
A major challenge in CoMFA and CoMSIA modeling is
alignment of molecules, which must be defined by the user. As
described in Text S1, multiple alignment approaches were
attempted. Despite the use of multiple alignments, the best
CoMFA and CoMSIA models consistently showed a large
difference between the correlation R
2 and cross-validated (XV-
R
2), whether modeling the entire set of steroidal compounds or the
various subsets (androstanes, bile salts, pregnanes). This suggests
that the CoMFA and CoMSIA models do not generalize beyond
the molecules in the training set, even for a subset of steroidal
compounds (Text S1, Tables S4, S5, S6, S7 and Figures S2, S3,
S4, S5, S6, S7).
Using the pharmacophore approach for the individual steroids, the
training set r values were quite low but increased upon inclusion of
excluded volumes with variable weight and tolerances (0.81–0.93)
(Table S8). All PXR pharmacophores (Figure S8) had at least 2
hydrophobes and a hydrogen bond acceptor in common (Text S1).
Using the pharmacophores derived from training sets based on subsets
of steroidal compounds (e.g., androstanes only) to predict the other
respective subsets did not result in reliable correlations (data not
shown),suggesting that highlyspecificpharmacophoreswere generated
or this may be due to the addition of the excluded volumes which limits
the chemical space of molecules mapping to the features. These class-
specific pharmacophores may therefore only be useful for making
predictions of very closely related molecules and even crossing steroidal
classes may be extrapolating too far beyond the training sets.
Table 1. Docking results for all of the 119 molecules to the six
hPXR crystal structures and the combined model in terms of
statistical parameters namely sensitivity (SE), specificity (SP),
overall prediction accuracy (Q) and matthews correlation
coefficient (C) are listed for models predicted with 17b-
estradiol similarity weighted goldscores and the values in
parenthesis are for models predicted with 5a-androstan-3b-ol
similarity weighted goldscores.
Structure SE (%) SP (%) Q (%) C (%)
1M13 (hyperforin ) 66.67(56.7) 55.06(53.9) 57.98(54.6) 0.19(0.09)
1NRL (SR12813) 46.67(60) 47.19(41.6) 47.06(46.2) 20.05(0.01)
1SKX (rifampicin) 53.33(70) 50.56(39.3) 51.26(47.1) 0.03(0.08)
2O9I (T0901317) 53.33(40) 50.56(40.4) 51.26(40.3) 0.03(20.17)
2QNV (colupulone) 53.33(46.7) 52.81(31.5) 52.94(35.3) 0.05(20.19)
EST (estradiol) 53.33(56.67) 50.56(49.44) 51.26(51.26) 0.02(0.05)
AVG 52 (55) 50.34 (42.69) 50.76(45.79) 0.02(20.02)
The values in AVG represent the average prediction rates.
doi:10.1371/journal.pcbi.1000594.t001
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CoMFA in modeling the compounds in the training sets using
three atom alignments (Table S9). One potential advantage of 4D-
QSAR relative to standard 3D-QSAR methods is the ability to
consider an ensemble of different ligand conformations, theoret-
ically increasing the chances of defining the active conformation.
The best 4D-QSAR models are found in Table S10 and Figure
S9, and generally predict steric/non-polar interactions between
ligand and receptor. Although the XV-R
2 for the best 4D-QSAR
models are better than for CoMFA and CoMSIA models of the
same training sets, the 4D-QSAR were poorly predictive of the
activity of compounds in the test set (Table S10).
5D - QSAR
4D- and 5D-QSAR have the advantage of being able to select
the bioactive conformation from a pool of possible binding modes
in parallel to the QSAR modeling stage. We have tested three
different alignment protocols in conjunction with the 5D-QSAR
technique Raptor.
(1) The top-1, top-2, top-5, top-10 and top-20 docking poses for
each ligand from our docking studies on 2QNV were
superimposed producing an alignment containing 115 –
2300 conformations for the 115 compounds in our dataset.
(2) All 115 compounds were automatically aligned onto 17b-
estradiol extracted from the complex structure with PXR.
Already aligned compounds were automatically added as
templates for aligning subsequent compounds. The order of
compounds in the alignment was determined based on their
experimental affinity towards PXR.
(3) As in (2) but each of the four substrate classes was aligned
separately on a template of the class selected by the lowest
Figure 1. Schematic representation of the binding mode of A. 5a-Androstan-3b-ol B epitestosterone sulfate C lithocholic acid
acetate and D levonorgestrol in the binding site of crystal structure of human PXR protein (PDB code: 1M13). The binding site residues
are colored by their nature, with hydrophobic residues in green and charged residues in purple. Blue spheres and contours indicate matching regions
between ligand and receptors. The schematic representations were generated using the LIGX option in MOE.
doi:10.1371/journal.pcbi.1000594.g001
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Bayesian model, B. Bad features from FCFP_6 Bayesian model. Asterisks can represent any atom. Numbers represent how many molecules out of the
total number possessing the fingerprint are active (good) or inactive (bad).
doi:10.1371/journal.pcbi.1000594.g002
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onto 17b-estradiol. The four individual alignments are then
combined into a 4D set for all 115 compounds.
In the alignment protocols (2) and (3) the protein crystal
structure was used as a forbidden (excluded) region. A penalty was
added to the similarity score for alignment solutions that
overlapped with the protein, thus physically impossible solutions
were removed from the alignment. As significant protein flexibility
is observed on the side chain level, all crystal structures were
aligned using PyMol [39]. Side chains that have different rotamer
states for different co-crystallized ligands were removed from the
forbidden region definition.
Our multidimensional QSAR study (software Raptor [40]) was
based on the same set of 115 molecules as described in the
CoMFA and CoMSIA studies. The dataset was split into 95
training set compounds, and 20 test set compounds identical to the
separation used in the CoMFA and CoMSIA studies. For 33
compounds only an upper limit for their Ki values has been
experimentally determined. These molecules defined the ‘‘thresh-
old class’’ (26 training, 7 test). A threshold value of 100 mM was
chosen considering that the lowest affinities were measured for this
dataset at approximately this value. To allow for topological and
physicochemical variation at the true biological receptor with
different ligands bound, the Raptor results were averaged over 10
individual models defining a surrogate conformational family.
For alignment (1) we were not able to derive QSAR models with
predictive models for leave-5-groups-out (r
2
CV-5) or cross-valida-
tion values (i.e..0.3). This is not surprising, as the identification of
bioactive binding modes using docking is difficult for this system
(see docking results). If we use an alignment with only the top-1 or
top-2 solutions, we most probably end up with an alignment
containing incorrect binding modes. Using the top-10 or top-20
binding modes generates too large a variety of contacts between
ligand and binding site model that the QSAR algorithm is not able
to extract the critical interactions throughout the binding site
modeling phase.
For alignment (2) a QSAR model with a r
2
CV-5 value of 0.55
could be generated, but with no observed correlation for the test
set. For alignment (3) a QSAR model with an r
2
CV-5 of 0.56 was
derived with a predictive r
2 for the test set of 0.45. The superior
model based on alignment (3) was due to the focused class-based
alignment process (Figure 3). The maximum deviation of predicted
from experimentally measured EC50 is 5.6 and 3.0 fold for training
and test set, respectively. Significantly higher regression coeffi-
cients can hardly be expected for this dataset considering the fact
that the threshold compounds have to be removed from the
calculation of the regression coefficients yielding a rather small
range in EC50 of 2.2 log units (Figure S10, Table S11). This is in
contrast to the CoMFA and CoMSIA simulations where the
threshold compounds have been assigned an EC50 value of
10,000 mM yielding a range of 4.1 log units. All except one of the
33 threshold compounds have been predicted with an EC50 value
lower than the given threshold or maximally a factor of 6.6 fold
higher. Only 5a-Androstane was predicted to have a 46 fold
higher value than the threshold. Thus, the model was able to
predict the affinity of compounds accurately and at the same time
was able to classify weak- or non-binding molecules correctly.
Discussion
It has been suggested that PXR forms a heterotetramer and
exhibits a range of motions which are key for its functioning and
preparing for coactivator binding at the Activator Function(AF-2)site
[41]. The large and promiscuous ligand binding pocket of PXR
accepts molecules of widely varying sizes (Table S1), and is likely
capable of binding small molecules in multiple orientations.
Furthermore, movement of regions of this pocket may be translated
elsewhere in the protein to influence protein-protein interactions.
Thus, the identification of the bioactive conformation of a ligand
binding to PXR (and the effect it might have as an agonist, antagonist
or allosteric antagonist [10]) and development of a ligand alignment
based on these conformations represents a challenge for any
computational technique. A realistic ligand alignment, however, is
the basis for a reliable 3D-QSAR model. Computational methods
including QSAR (3D, 4D and 5D), pharmacophores and machine
learningclassificationmodelsforPXRcanassistinrapidpredictionof
whether a compound is likely to be an agonist (activator), however
each method has its limitations and advantages (Table 2). For
example a previous study used human PXR activation data for 30
steroidal compounds (including 9 bile acids) to create a pharmaco-
phore with four hydrophobic features and one hydrogen bond
acceptor [27]. This pharmacophore contained 5a-androstan-3b-ol
(EC50 0.8 mM) which contains one hydrogen bond acceptor,
indicating that in contrast to the crystal structure of 17b-estradiol
(published EC50 20 mM) bound to human PXR with two hydrogen
bonding interactions [19], hydrophobic interactions may therefore be
more important for increased affinity [27]. This and other
pharmacophores have been used to predict PXR interactions for
antibiotics [35] which were verified in vitro, suggesting one use for
computational approaches in combination with experimental
methods.
To our knowledge there has been no comparative analysis of the
steroidal classes with respect to their use as PXR agonists. The use
of the Bayesian classification with 2D fingerprints represents a low
computational cost approach [42] which has been used frequently
with large molecule datasets [43–46]. Using 2D-molecular
fingerprint descriptors identified regions in the training set
molecules that were predominantly hydrophobic and that were
important for PXR activation. Substructures with free hydroxyls
as hydrogen bonding features were associated with compounds
that were not activators. This is in general agreement with other
studies which have used docking to try to help design out PXR
activation [38]. This model was able to successfully rank a large
test set (Table S3) of non-steroidal molecules, indicative that the
molecular descriptors adequately captured the global properties of
PXR agonists and suggests some utility.
The current study suggests that while it is generally possible to
create 3D-QSAR (CoMFA, CoMSIA, Catalyst) and 4D-QSAR
models that can be cross-validated, these models perform poorly
when used to predict external molecules. Only the 5D-QSAR model
generated displays some success in predicting external test set
steroidal compounds. Three main differences between the 5D-QSAR
and the 3D-QSAR studies that might contribute to the difference in
performance are the less rigid alignment using Symposar [40], the
possibility to present a ligand in more than one binding pose and the
better treatment of weak or non-binding compounds.
Pharmacophore models for the 4 classes of steroidal compounds
possessed some of the features in the published human PXR
crystal structures, however the models contained two or three
hydrophobic regions (rather than four as shown previous-
ly)[27,28,31] and one to two hydrogen bond acceptors or a
hydrogen bond acceptor and hydrogen bond donor (compared to
one hydrogen bond acceptor as shown previously). This might
suggest that the steroids evaluated occupy just a part of the ligand
binding pocket while larger molecules like rifampicin occupy most
of the binding pocket and have subsequently many more
interactions with the protein [17]. The addition of the excluded
volumes to the pharmacophores was shown to improve the
Predicting Interactions with Promiscuous Proteins
PLoS Computational Biology | www.ploscompbiol.org 6 December 2009 | Volume 5 | Issue 12 | e1000594Figure 3. Receptor model for PXR obtained using Raptor (beige-brown, hydrophobic properties; red, hydrogen bond acceptor;
blue, hydrogen-bond donor; and green, hydrogen bond donor/acceptor). The most active ligand of each of the four substrate classes
aligned to each other is displayed as sticks. A: Inner shell is displayed in surface representation, outer shell in wireframe. B: The bulky right portion of
the outer shell corresponds to the solvent exposed region of the ligand alignment. It is dominated by a mixed hydrogen bond donor/acceptor
character in agreement with solvent exposure.
doi:10.1371/journal.pcbi.1000594.g003
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to using the crystal structures in 5D-QSAR.
Consistent with the QSAR findings were those from docking
studies that though modest in success overall, fare much better
with individual classes of compounds. The classification was
performed using two similarity weighted scoring schemes: one
based on a highly potent compound 5a-androstan-3b-ol and the
other based on a structurally relevant compound 17b-estradiol.
The goal was to test the utility of biasing the scoring scheme with
either a structurally relevant compound or a functionally
significant compound.
However, in this case 17b-estradiol and 5a-androstan-3b-ol
share nearly 75% structural similarity (using MDL Keys and
Tanimoto similarity coefficient). The results from the classification
studies showed that biasing the scoring scheme with a structurally
relevant compound (17b-estradiol) produced classification rates
with sensitivity and specificity values averaging at 52% and 50%
respectively with slightly better prediction accuracy (Table 1).
These results unfortunately cannot be compared with our recent
docking study [47] as a different co-crystal ligand was used for the
scoring scheme. Although the structure biased scoring scheme
performed better among all the compounds, both the scoring
schemes performed equally well when individual classes were
considered. In the case of androstanes, 6 out of 11 compounds
were correctly predicted as activators in docking studies. 5a-
Androstan-3b-ol that had the lowest EC50 value (described earlier)
was predicted to be an activator in all structures. 5a-Androstan-
3b-ol binds with very high docking scores and has a hydrogen
bond interaction with His407, a key interaction of PXR
(Figure 1A). This interaction was consistent among all the
androstane activators. However, epitestosterone sulfate has an
EC50 of 3.39 mM and was misclassified in the combined model
using predictions from all structures as a non-activator. Docking
studies show that epitestosterone sulfate has a consistently reversed
docking pose (when compared with 5a-Androstan-3b-ol) in all the
models and the sulfate group is predicted to make a hydrogen
bond interaction with His407, as opposed to the steroid ester in
1M13 structure (Figure 1B). A few other misclassified activators
were docked in reversed poses and often had favorable hydrogen
bonding partners such as sulfates that probably influence the
binding mode of these steroids. This is a surprising and novel
finding of this study and other researchers should be aware of this
when docking similar compounds with this functional group.
Among the bile salts, all four activators were correctly predicted
and the ligands bind in a conserved mode with the steroid esters
participating in favorable interactions with the side chain of
His407 and Arg410, and the steroid rings with hydrophobic
groups such as Leu411, Leu239 and Phe281 (Figure 1C). The
pregnanes had similar activation patterns as the bile salts and
docking studies could predict 4 out of the 9 compounds correctly.
Among the misclassified compounds, levonorgestrol was predicted
to be an activator in three models, and a non-activator in three
models and hence could not be classified with high confidence.
Levonorgestrol has an EC50 of 4.30 mM and is predicted to have
favorable interactions with hPXR as shown in Figure 1D. Despite
this, the similarity weighted scoring functions generally performed
well in classifying activators as described in the examples above
and by the sensitivity values in Table 1. The paucity of available
PXR binding data may limit some of the insights from docking
experiments performed to date.
It is not surprising that CoMFA and CoMSIA do not perform
well as they use rigid alignments of the molecules. This is potentially
a seriously limitation given that the binding pocket of PXR may
accommodate multiple orientations of the steroids (Figure 1A vs.
Figure 1B). Theoretically, 4D- and 5-QSAR should perform better
by considering an ensemble of ligand conformations and in fact 4D-
QSAR does well within subsets (especially androstanes) but like all
methods extrapolates poorly. 5D-QSAR appears to perform the
best with the test set. Alignment independent methods like Catalyst
which can deal with structurally diverse molecules can generate
pharmacophores for the individual classes of compounds but their
inter-class predictivity is limited. Another alignment independent
method such as using 2D fingerprints and descriptors with the
Bayesian classification approach may represent a fast approach to
screen for potential PXR agonists, but like all methods their
applicability domain [48,49] is dependent on the training set. In this
case the set of steroids would be expected to limit the utility of such
models to a relatively narrow class of compounds, although it may
be picking up key features in more diverse molecules (Table S3)
suggesting overlap in the chemical space.
This study shows the inherent difficulty of producing predictive
ligand or structure-based computational models for PXR. Some of
Table 2. Summary of the different methods used in this study.
Method Advantages Limitations
Bayesian Classification with 2D Fingerprints
and interpretable descriptors
Computationally fast and cheap model generation,
illustration of features important for activity
Cannot deal with stereoisomers, not quantitative,
requires quite large training sets
3D-QSAR :Catalyst Can use structurally diverse molecules, can add excluded
volumes, quantitative, interpretable, starts from multiple
conformations.
Models may not be useful beyond a narrow compound
class, conformations may not be biologically relevant
3D-QSAR: CoMFA, COMSIA Widely used methods and useful for drug design
and analog modification.
Molecules require manual alignment and this may be a
major limitation in this study
4D-QSAR Considers an ensemble of different ligand
conformations to define the active conformation
Computationally expensive, Alignment strategy may be
a limitation
5D-QSAR Considers an ensemble of different ligand conformations
to define the active conformation in parallel, less rigid
alignment, better treatment of weak binders.
Computationally expensive, Alignment strategy may be
a limitation. For alignment crystal structures may not
amply take into account the protein flexibility however
in Raptor this is treated explicitly, exclusion areas could
be too harsh.
GOLD docking and scoring May provide potential binding orientation with respect
to pocket which could be verified by site directed
mutagenesis
Relatively slow, defining the binding site is key in such a
large pocket
doi:10.1371/journal.pcbi.1000594.t002
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alignment independent, and each has limitations when used with
flexible proteins. These computational models also confirm some
of the molecular features (hydrophobicity and hydrogen bond
acceptors) identified in previous models and structures, while using
a large quantitative dataset to create new QSAR, classification and
pharmacophore models to test docking and scoring. The study
represents an initial step comparing multiple methods focused on
steroidal compounds rather than a more diverse series of drug-like
molecules. Using a more diverse series of molecules would have
been expected to present even more difficulty for the alignment
dependent methods such as CoMFA and CoMSIA. There are also
many more commercial computational methods that could be
evaluated and compared, although we have used several 3D, 4D,
5D-QSAR methods, machine learning with 2D descriptors,
pharmacophore and GOLD docking and scoring methods in this
study. The results from these methods could be used in
combination as part of a consensus approach or Pareto
optimization [50]. The provision of the 115 molecule human
PXR dataset is potentially useful as a benchmark PXR set for
testing further methods in future. For example, flexible docking
methods [51] could be used as well as algorithms that could
differentiate multiple binding mechanisms [52].
In conclusion, there are many promiscuous proteins [34] where the
modeling of ligand-protein interactions is complicated by a large
binding site, multiple binding pockets, protein flexibility or all of the
preceding. We have applied several different computational approach-
es which could also be applied to other proteins like CYPs, transporters
and ion channels. This work is therefore more broadly applicable in an
attempt to predict whether molecules bind in such flexible proteins,
and which methods perform the best. Depending on the desired use of
such information, different modeling methods may be appropriate and
required. While 2D methods do not encode 3D information like shape
[53] they are fast and they can highlight important features likely
interacting with the protein. 3D-5D methods provide more shape
based information but they are fragile, with a narrow applicability
domain and may not be able to differentiate close analogs. Docking is
also limited unless key interactions with the protein are already known.
Our results suggest that even in the presence of multiple crystal
structures, the full range of protein motions may not be captured. As
we have previously shown, when docking classification predictions are
correct the binding conformation information alone may be instructive
[13]. This current analysis indicates that using many different
computational approaches (both alignment dependent and alignment
independent) may be necessary and expectations should be scaled
accordingly if some do not work with such promiscuous proteins. Even
with their respective limitations, these methods have provided some
useful information of general interest that could be applicable beyond
PXR.
Methods
Experimental Methodology and Datasets
Human PXR activation was determined by a luciferase-based
reporter assay as has been previously described [21,33,34]. The
datasets modeled in this study were collected by a consistent
protocol and have been previously published [31,54]. Experimen-
tal data for four classes of steroidal compounds, namely
androstanes, estratrienes, pregnanes and bile acids/ salts are
shown in Table S2.
In Silico Methodology: Docking and Scoring
All molecules described in Table S2 were used for docking
experiments. The molecules were docked into these six crystallized
structures of human PXR (PDB IDs 1M13, 1NRL, 1SKX, 2O9I,
2QNV and one structure co-crystallized with 17b-estradiol that is
not in the PDB identified here as EST). In all cases, the crystal
structure ligand was removed, and hydrogen atoms were added to
the amino acids. All amino acids within 6 A ˚ of the co-crystallized
ligand were identified as the binding site. The docking program
GOLD (ver 4 [55]) was used for docking all compounds to the
binding sites of each PXR crystal structure. GOLD uses genetic
algorithm to explore the various conformations of ligands and
flexible receptor side chains in the binding pocket. Further, 20
independent docking runs were performed for each ligand. The
docked complexes were scored with goldscore [55] and then
rescored using similarity weighted scoring scheme (SWscore). For
each ligand, the best ranking conformation’s goldscore denoted by
Si was used to derive the SWscore shown in equation 1. The
similarity scores Wi were computed based on 2D similarity
encoded in MDL fingerprint keys calculated using Discovery
Studio 2.1 (Accelrys, San Diego, CA, USA). The Tanimoto
coefficient was used as the metric to compare the molecular
fingerprints. The coefficients varied between 0 and 1, where 0
meant maximally dissimilar and 1 coded for maximally similar.
The Tanimoto coefficient between fingerprints X and Y has been
defined to be: [number of features in intersect (A, B)]/[number of
features in union (A,B)], where A and B are two compounds.
So the SWscore is given by, SWscore = Wi*Si, where Wi was
the similarity score of compound i against 5a-Androstan-3b-ol
which had the best EC50 value of 0.8 mM for PXR or 17b-
estradiol which had a steroid core that was present in most of the
compounds. Further, the quality of the scoring function was
assessed using standard statistical indicators namely sensitivity
(SE), specificity (SP), overall prediction accuracy (Q) and Matthews
correlation coefficient (C) (Table 1) and were derived as described
previously [22].
In Silico Methodology: Machine Learning with 2D
Descriptors
Bayesian models were generated using Discovery Studio 2.1
(Accelrys, San Diego, CA) Laplacian-corrected Bayesian classifier
[37,42,43,45,56]. FCFP_6 fingerprints, AlogP, molecular weight,
number of rotatable bonds, number of rings, number of aromatic
rings, number of hydrogen bond acceptors, number of hydrogen
bond donors and molecular fractional polar surface area were
calculated from the input sdf file using the ‘‘calculate molecular
properties protocol’’. The ‘‘create Bayesian model protocol’’ was
used for model generation and a custom protocol for validation
(leave out 20% 100 times) was used.
In Silico Methodology: 5D-QSAR - Symposar and Raptor
5D-QSAR studies were performed using Raptor [40]. Raptor
includes the possibility of representing each ligand molecule as an
ensemble of conformations, orientations, stereoisomers and
protonation states (4D-QSAR), thereby reducing the bias in
identifying the bioactive conformer. In addition, it explicitly allows
for induced fit by a dual-shell representation of the three-
dimensional binding-site model, onto which the physicochemical
properties (hydrophobicity and hydrogen-bonding propensity) are
mapped (5D-QSAR). The inner shell is tailored using the most
potent ligand of the training set, the outer shell accommodates the
topology of all molecules from the training set. The adaptation of
both field and topology of the receptor surrogate to each ligand is
achieved by combining a steric adjustment to the topology of every
ligand and a term due to the attraction or repulsion between
ligand and receptor model. The latter is obtained by correlating
their physicochemical properties (hydrophobicity and hydrogen-
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onto the shells is not unambiguously determinable, different
models with similar predictive power can be identified. Raptor
generates a family of receptor models. Such model families may be
interpreted to represent the various configuration states of the true
biological receptor. The obtained binding affinities are averaged
over the individual models.
The underlying scoring function for evaluating ligand-protein
interactions includes directional terms for hydrogen bonding
(DGHbond), hydrophobicity (DGHphob) as well as terms for the
cost of the topological adaptation (DGIF) and the changes in
entropy (TDS) upon ligand binding: DGbinding=DGconstant +
DGHbond + DGHPhob 2 TDS + DGIF .
Experimental determination of binding affinity for weak
inhibitors is often prevented due to limited solubility or limited
sensitivity. Thus, only an upper limit (‘threshold’) for Ki values
is accessible. To prevent artificial assignment of affinities in a
QSAR study including weak binders, the Raptor concept
allows the use of a threshold option: the optimization
algorithm forces the model to reproduce the binding affinity
of the weak- and non-binding ligand molecules to be lower
than the experimental limit. Obviously, compounds which are
experimentally measured to bind weaker than a threshold Ki(t)
and are correctly classified during the model optimization, no
penalty is added to the lack-of-fit value, if, on the other hand,
the binding affinity of the ligand is predicted higher than the
threshold, the lack-of-fit function applies a penalty propor-
tional to DGbinding(t) 2 DGbinding.
4D sets of alternative conformations for each ligand as input for
Raptor were performed with Symposar [57]. In Symposar the
ligand molecules are superimposed onto one or several template
molecules, first, on the basis of fuzzy-like 2D substructure
similarities and, subsequently, in 3D space with respect to their
similarity of physicochemical fields. This two-step process
combines the speed of a 2D similarity search with the accuracy
and authenticity of protein-ligand interactions in 3D space. The
molecules are thereby treated as flexible and are fully relaxed at
the end of the alignment process.
Supporting Information
Table S1 Molecular descriptors for PXR crystal structure
ligands calculated with Discovery Studio ver 2.1 (Accelrys, San
Diego, CA).
Found at: doi:10.1371/journal.pcbi.1000594.s001 (0.01 MB PDF)
Table S2 Dataset of human PXR activation used for modeling
studies.
Found at: doi:10.1371/journal.pcbi.1000594.s002 (0.04 MB PDF)
Table S3 Test set [13] prediction with Bayesian model
(activator=EC50,100 mM, non-activator=EC50.100 mM).
Found at: doi:10.1371/journal.pcbi.1000594.s003 (0.02 MB PDF)
Table S4 CoMFA Test Set Predictions
Found at: doi:10.1371/journal.pcbi.1000594.s004 (0.02 MB PDF)
Table S5 To identify which outliers are bringing down the XV-
R2 of the CoMFA model, the following table lists the activities as
predicted by the cross-validated PLS model: The standard
deviation of the residuals in the following table is 0.825, and
accordingly, the two possible outliers are highlighted. The two
outliers are the only two inactives in the training set.
Found at: doi:10.1371/journal.pcbi.1000594.s005 (0.02 MB PDF)
Table S6 CoMFA outlier analysis.
Found at: doi:10.1371/journal.pcbi.1000594.s006 (0.02 MB PDF)
Table S7 Test set predictions for CoMFA and CoMSIA models.
Found at: doi:10.1371/journal.pcbi.1000594.s007 (0.02 MB PDF)
Table S8 Best model training set correlation (r) values and
model statistics (total cost and null cost) for Catalyst Hypogen
hypotheses.
Found at: doi:10.1371/journal.pcbi.1000594.s008 (0.01 MB PDF)
Table S9 Three-ordered atom alignments (based on the
steroidal core) used in the 4D- QSAR analysis.
Found at: doi:10.1371/journal.pcbi.1000594.s009 (0.01 MB PDF)
Table S10 External Validation test Set Predictions for 4D-
QSAR
Found at: doi:10.1371/journal.pcbi.1000594.s010 (0.02 MB PDF)
Table S11 Experimental versus predicted pEC50 values for 115
compounds binding to PXR divided into four different substrate
classes - 5D-QSAR.
Found at: doi:10.1371/journal.pcbi.1000594.s011 (0.03 MB PDF)
Text S1 In silico methodology: 3D-QSAR - CoMFA, CoMSIA,
In silico methodology: 3D-QSAR - Catalyst, In silico methodol-
ogy: 4D-QSAR, Supplemental results: CoMFA, CoMSIA and
Catalyst. Supplemental data - pharmacophores output files from
Discovery Studio Catalyst.
Found at: doi:10.1371/journal.pcbi.1000594.s012 (0.08 MB PDF)
Figure S1 Structural superposition of six PXR crystal structures
are shown in ribbon models and colored 1M13 (red), 1NRL
(orange), 1SKX (cyan), 2O9I (blue), 2QNV (yellow) and PXR-
EST (brown). The co-crystallized ligands are shown as sticks and
colored blue for rifampicin, orange for colupulone, dark green for
hyperforin, light green for N-{4-[2,2,2-trifluoro-1-hydroxy-1-
(trifluromethyl)-ethyl]phenyl}benzenesulfonamide and pink for
17b-estradiol.
Found at: doi:10.1371/journal.pcbi.1000594.s013 (0.68 MB TIF)
Figure S2 CoMFA models for androstanes. A 5a-Androstan-3b-
ol (pIC50=6.1) shown with the steric component of the CoMFA
model. Green denotes areas where steric bulk is favorable for
bioactivity while yellow shows areas where steric bulk is not
favored. B 5a-Androstan-3b-ol shown with the electrostatic
component of the CoMFA model. Blue denotes areas where
positive charge is favorable for bioactivity while red shows areas
where negative charge is favored.
Found at: doi:10.1371/journal.pcbi.1000594.s014 (0.22 MB TIF)
Figure S3 CoMSIA models for androstanes. A - 17b-dihy-
droandrosterone (pIC50=5.38) with the steric component of the
CoMSIA model. Blue denotes areas where steric bulk is favorable
for bioactivity while red shows areas where steric bulk is not
favored. B 17b-dihydroandrosterone with the hydrophobic
component of the CoMSIA model. Purple denotes areas where
hydrophobic groups are favorable for bioactivity while grey shows
areas where hydrophobic groups are not preferred. C 17b-
dihydroandrosterone with the hydrogen bond acceptor compo-
nent of the CoMSIA model. Blue denotes areas where acceptor
groups are favorable for bioactivity while red shows areas where
acceptor groups are not preferred.
Found at: doi:10.1371/journal.pcbi.1000594.s015 (0.24 MB TIF)
Figure S4 CoMFA models for pregnanes. A Pregnanedione
(pIC50=5.59) shown with the steric component of the CoMFA
model. Green denotes areas where steric bulk is favorable for
bioactivity while yellow shows areas where steric bulk is not
favored. B Pregnanedione shown with the electrostatic component
of the CoMFA model. Blue denotes areas where positive charge is
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charge is favored.
Found at: doi:10.1371/journal.pcbi.1000594.s016 (0.26 MB TIF)
Figure S5 CoMSIA models for Pregnanes. A. Inactive training
set molecule Pregnenolone Carbonitrile (PCN) (pIC50=2.00) with
the steric component of the CoMSIA model. Blue denotes areas
where steric bulk is favorable for bioactivity while red shows areas
where steric bulk is not favored. B Inactive training set molecule
PCN shown with the electrostatic component of the CoMSIA
model. Blue denotes areas where positive charge is favorable for
bioactivity while red shows areas where negative charge is favored.
C. Inactive training set molecule PCN with the hydrophobic
component of the CoMSIA model. Purple denotes areas where
hydrophobic groups are favorable for bioactivity while grey shows
areas where hydrophobic groups are not preferred.
Found at: doi:10.1371/journal.pcbi.1000594.s017 (0.23 MB TIF)
Figure S6 A. CoMFA models for bile acids and bile salts.
Lithocholic acid acetate (pIC50=5.92) shown with the steric
component of the CoMFA model. Green denotes areas where
steric bulk is favorable for bioactivity while yellow shows areas
where steric bulk is not favored. B Lithocholic acid acetate shown
with the electrostatic component of the CoMFA model. Blue
denotes areas where positive charge is favorable for bioactivity
while red shows areas where negative charge is favored.
Found at: doi:10.1371/journal.pcbi.1000594.s018 (0.27 MB TIF)
Figure S7 CoMSIA models of bile acids and bile salts. Using the
PLS focused region, CoMSIA components were calculated. A.
Hyodeoxycholic acid (pIC50 =4.42) shown with electrostatic
components of the CoMSIA model. Blue denotes areas where
positive charge is favorable for bioactivity while red shows areas
where negative charge is favored. B. Hyodeoxycholic acid with the
hydrophobic component of the CoMSIA model. Purple denotes
areas where hydrophobic groups are favorable for bioactivity while
grey shows areas where hydrophobic groups are not preferred. C.
Hyodeoxycholic acid with the hydrogen bond donor component
of the CoMSIA model. Blue denotes areas where donor groups are
favorable for bioactivity while red shows areas where donor groups
are not preferred.
Found at: doi:10.1371/journal.pcbi.1000594.s019 (0.31 MB TIF)
Figure S8 Catalyst PXR pharmacophores A. Bile acids, B.
Estratrienes, C. Androstanes, D Pregnanes pharmacophore
features represent Green=hydrogen bond acceptor, purple=
hydrogen bond donor, blue=Hydrophobic, gray=excluded
volumes.
Found at: doi:10.1371/journal.pcbi.1000594.s020 (0.15 MB TIF)
Figure S9 A. 4D-QSAR for androstanes showing the active
conformation of 5a-Androstan-3b-ol, B 4D-QSAR for pregnanes
showing the active conformation of pregnanolone, C 4D-QSAR
for bile acids/salts showing the active conformation of lithocholic
acid acetate.
Found at: doi:10.1371/journal.pcbi.1000594.s021 (0.19 MB TIF)
Figure S10 5D-QSAR Experimental versus predicted pEC50
values for 115 compounds binding to PXR. Training set
compounds are displayed in green, test set compounds in red.
Threshold compounds are placed at an experimental pEC50 value
of 2 to better separate them visually from the other molecules.
Found at: doi:10.1371/journal.pcbi.1000594.s022 (0.11 MB TIF)
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